Kurzfassung

A phase 3, randomized, double‑blind, placebo‑controlled, multicenter study of Bendamustine and Rituximab (BR) alone versus in combination with Acalabrutinib (ACP‑196) in subjects with previously untreated Mantle Cell Lymphoma